Table 3.
Patterns of reactivity with citrullinated and/or noncitrullinated rat filaggrin of sera obtained from patients with different rheumatic diseases and healthy individuals (group 1)
| ACRF+ | ACRF– | ACRF+and ANCRF+ | |||||
|---|---|---|---|---|---|---|---|
| Group 1 Subgroup | ANCRF– | ANCRF+ | ANCRF– | ACNRF+ | ANCRF < ACRF* | ANCRF = ACRF* | ANCRF > ACRF* |
| 1a: | |||||||
| RA (n = 101) | 51 (50·4) | 13 (12·9) | 35 (34·6) | 2 (2) | 10 (9·9) | 1 (1) | 2 (2) |
| 1b: | |||||||
| SLE (n = 32) | 0 | 12 (37·5) | 14 (43·8) | 6 (18·8) | 0 | 0 | 12 (37·5) |
| SS (n = 26) | 1 (3·8) | 13 (50) | 10 (38·5) | 2 (7·7) | 0 | 2 (7·7) | 11 (42·3) |
| SPA (n = 69) | 0 | 34 (49·3) | 29 (42) | 6 (8·7) | 0 | 15 (21·7) | 19 (27·5) |
| 1c: | |||||||
| Controls (n = 96) | 0 | 18 (18·8) | 63 (65·6) | 15 (15·6) | 0 | 4 (4·2) | 14 (14·6) |
Results are expressed in number of patients (%). ACRF, anti-citrullinated rat filaggrin; ANCRF, anti-non-citrullinated rat filaggrin; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SS, primary Sjögren's syndrome; SPA, spondylarthropathy.
*
OD comparisons.